Posted by Michael Wonder on 04 Jan 2017
FDA accepts for filing supplemental new drug application for Lilletta (levonorgestrel-releasing intrauterine system)
4 January 2017 - Application seeks to extend duration of use up to 4 years.
Allergan and Medicines360 today announced that the U.S. FDA has accepted for filing the company's supplemental new drug application to potentially extend the duration of use for the prevention of pregnancy from up to three years to up to four years for Liletta (levonorgestrel-releasing intrauterine system).
